Biopharma firm Incyte's Q1 revenue, adjusted profit beat estimates

Incyte

28/04/2026 12:09

Overview

U.S. biopharma firm's Q1 revenue rose 21% yr/yr, beating analyst expectations

Adjusted EPS for Q1 beat analyst expectations

Growth driven by higher demand for Jakafi, Opzelura, and hematology/oncology products

Outlook

Incyte reaffirms 2026 total net sales guidance of $4.77-$4.94 bln

Company maintains 2026 Jakafi net sales forecast at $3.22-$3.27 bln, including Jakafi XR launch

Incyte expects regulatory decisions and potential launches for Jakafi XR and Opzelura in EU in mid-to-late 2026

Result Drivers

JAKAFI DEMAND - Co said Jakafi net sales rose 7% on higher paid demand and growth across all indications

OPZELURA GROWTH - Opzelura net sales rose 20% on increased patient demand in atopic dermatitis and vitiligo

HEMATOLOGY/ONCOLOGY PORTFOLIO - Hematology and oncology net sales rose 116% driven by increased demand for Niktimvo, Monjuvi/Minjuvi and Zynyz

Company press release: ID:nBw83xyCYa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$1.27 bln
$1.21 bln (18 Analysts)
Q1 Adjusted EPS
Beat
$1.81
$1.37 (16 Analysts)
Q1 EPS
$1.47
Q1 Adjusted Operating Income
Beat
$393.67 mln
$328.48 mln (12 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 15 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Incyte Corp is $106.50, about 11.3% above its April 27 closing price of $95.72

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 13 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)